Skip to main content
Top
Published in: Pathology & Oncology Research 2/2019

01-04-2019 | Original Article

Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer

Authors: Haochang Hu, Tiangong Wang, Ranran Pan, Yong Yang, Bin Li, Cong Zhou, Jun Zhao, Yi Huang, Shiwei Duan

Published in: Pathology & Oncology Research | Issue 2/2019

Login to get access

Abstract

Colorectal cancer (CRC) is one of the leading causes of death worldwide. Aberrant DNA methylation has been recognized as one of the most common molecular alterations in CRC. The goal of this study was to investigate the diagnostic value of SFRP1 and SFRP2 methylation for CRC. A total of 80 pairs of CRC patients were recruited to test the association of SFRP1 and SFRP2 promotor methylation with CRC. Methylation assay was performed using quantitative methylation-specific polymerase chain reaction (qMSP) method. In this study, we found the methylation levels of SFRP1 and SFRP2 in CRC tumor tissues were significantly higher than those in the adjacent non-tumor tissues (SFRP1: P = 2E-5; SFRP2: P = 0.014). Further bioinformatics analysis of TCGA data confirmed the association of the two genes with CRC (SFRP1: P = 7E-21; SFRP2: P = 5E-24). Luciferase reporter gene assay showed that the recombinant plasmids with SFRP1 and SFRP2 fragments could significantly enhance promoter activity (SFRP1: P = 0.002; SFRP2: P = 0.004). In addition, SFRP1 and SFRP2 methylation were inversely correlated with the mRNA expression displayed by TCGA data mining (SFRP1: r = −0.432, P = 4E-11; SFRP2: r = −0.478, P = 1E-13). GEO data analysis indicated that SFRP1 and SFRP2 expression were increased in three CRC cell lines (COLO320, HCT116 and HT29) after 5′-AZA-deoxycytidine treatment, suggesting that DNA methylation played an important role in regulating gene expression of the two genes. Our results confirmed that promoter methylation of SFRP1 and SFRP2 contributed to the risk of CRC.
Literature
1.
go back to reference Huang J, Tan ZR, Yu J, Li H, Lv QL, Shao YY, Zhou HH (2017) DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma. Onco Targets Ther 10:4739–4751CrossRefPubMedPubMedCentral Huang J, Tan ZR, Yu J, Li H, Lv QL, Shao YY, Zhou HH (2017) DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma. Onco Targets Ther 10:4739–4751CrossRefPubMedPubMedCentral
2.
go back to reference Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, Yang P, Chen S, Ye M, Duan S (2017) DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene 630:1–7CrossRefPubMed Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, Yang P, Chen S, Ye M, Duan S (2017) DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene 630:1–7CrossRefPubMed
3.
go back to reference Hu H, Chen X, Wang C, Jiang Y, Li J, Ying X et al (2017) The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget 8:84054–84065PubMedPubMedCentral Hu H, Chen X, Wang C, Jiang Y, Li J, Ying X et al (2017) The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget 8:84054–84065PubMedPubMedCentral
4.
go back to reference Dashwood RH (1999) Early detection and prevention of colorectal cancer (review). Oncol Rep 6:277–281PubMed Dashwood RH (1999) Early detection and prevention of colorectal cancer (review). Oncol Rep 6:277–281PubMed
5.
go back to reference Wu D, Chen X, Xu Y, Wang H, Yu G, Jiang L, Hong Q, Duan S (2017) Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma. Oncol Lett 13:2745–2750CrossRefPubMedPubMedCentral Wu D, Chen X, Xu Y, Wang H, Yu G, Jiang L, Hong Q, Duan S (2017) Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma. Oncol Lett 13:2745–2750CrossRefPubMedPubMedCentral
6.
go back to reference Liu S, Chen X, Chen R, Wang J, Zhu G, Jiang J et al (2017) Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget 8:36354–36367PubMedPubMedCentral Liu S, Chen X, Chen R, Wang J, Zhu G, Jiang J et al (2017) Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget 8:36354–36367PubMedPubMedCentral
8.
go back to reference Piras G, Monne M, Palmas AD, Calvisi A, Asproni R, Vacca F, Pilo L, Gabbas A, Latte G (2014) Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma. Clin Epigenetics 6:16CrossRefPubMedPubMedCentral Piras G, Monne M, Palmas AD, Calvisi A, Asproni R, Vacca F, Pilo L, Gabbas A, Latte G (2014) Methylation analysis of the phosphates and tensin homologue on chromosome 10 gene (PTEN) in multiple myeloma. Clin Epigenetics 6:16CrossRefPubMedPubMedCentral
10.
go back to reference Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F et al (2013) Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol 8:199PubMedPubMedCentral Chen C, Wang L, Liao Q, Huang Y, Ye H, Chen F et al (2013) Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer. Diagn Pathol 8:199PubMedPubMedCentral
11.
go back to reference Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J (2012) CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res 18:263–270CrossRefPubMed Wang Z, Yuan X, Jiao N, Zhu H, Zhang Y, Tong J (2012) CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Pathol Oncol Res 18:263–270CrossRefPubMed
12.
go back to reference Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S (2017) Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics 9:126CrossRefPubMedPubMedCentral Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S (2017) Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin Epigenetics 9:126CrossRefPubMedPubMedCentral
13.
go back to reference Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY, Han ZG (2007) Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7:126CrossRefPubMedPubMedCentral Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY, Han ZG (2007) Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7:126CrossRefPubMedPubMedCentral
14.
go back to reference Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E et al (2011) Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama 65:169–177PubMed Takeda M, Nagasaka T, Dong-Sheng S, Nishie H, Oka T, Yamada E et al (2011) Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama 65:169–177PubMed
15.
go back to reference Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, Choi KY, Kim H, Kim HO, Jeong KU, Chun HK, Kim K, Park DI (2017) Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res 15:495–501CrossRefPubMedPubMedCentral Park SK, Baek HL, Yu J, Kim JY, Yang HJ, Jung YS, Choi KY, Kim H, Kim HO, Jeong KU, Chun HK, Kim K, Park DI (2017) Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population? Intest Res 15:495–501CrossRefPubMedPubMedCentral
16.
go back to reference Bartak BK, Kalmar A, Peterfia B, Patai AV, Galamb O, Valcz G et al (2017) Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12:751–763CrossRefPubMedPubMedCentral Bartak BK, Kalmar A, Peterfia B, Patai AV, Galamb O, Valcz G et al (2017) Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12:751–763CrossRefPubMedPubMedCentral
17.
go back to reference Babaei H, Mohammadi M, Salehi R (2016) DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J 57:242–245CrossRefPubMedPubMedCentral Babaei H, Mohammadi M, Salehi R (2016) DNA methylation analysis of secreted frizzled-related protein 2 gene for the early detection of colorectal cancer in fecal DNA. Niger Med J 57:242–245CrossRefPubMedPubMedCentral
18.
go back to reference Zhang H, Zhu YQ, Wu YQ, Zhang P, Qi J (2014) Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol 20:6329–6335CrossRefPubMedPubMedCentral Zhang H, Zhu YQ, Wu YQ, Zhang P, Qi J (2014) Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol 20:6329–6335CrossRefPubMedPubMedCentral
19.
go back to reference Huang Z, Li L, Wang J (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52:2287–2291CrossRefPubMed Huang Z, Li L, Wang J (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 52:2287–2291CrossRefPubMed
20.
go back to reference Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883–888CrossRefPubMed Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, Chughtai S, Wallis Y, Matthews GM, Morton DG (2004) The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64:883–888CrossRefPubMed
21.
go back to reference Li B, Chen X, Jiang Y, Yang Y, Zhong J, Zhou C, Hu H, Duan S (2017) CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population. Immunol Lett 190:15–19CrossRefPubMed Li B, Chen X, Jiang Y, Yang Y, Zhong J, Zhou C, Hu H, Duan S (2017) CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population. Immunol Lett 190:15–19CrossRefPubMed
22.
go back to reference Cannas V, Daino GL, Corona A, Esposito F, Tramontano E (2015) A luciferase reporter gene assay to measure Ebola virus viral protein 35-associated inhibition of double-stranded RNA-stimulated, retinoic acid-inducible gene 1-mediated induction of interferon beta. J Infect Dis 212(Suppl 2):S277–S281CrossRefPubMed Cannas V, Daino GL, Corona A, Esposito F, Tramontano E (2015) A luciferase reporter gene assay to measure Ebola virus viral protein 35-associated inhibition of double-stranded RNA-stimulated, retinoic acid-inducible gene 1-mediated induction of interferon beta. J Infect Dis 212(Suppl 2):S277–S281CrossRefPubMed
23.
go back to reference Yu J, Zhai X, Li X, Zhong C, Guo C, Yang F, Yuan Y, Zheng S (2017) Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci Rep 7:14265CrossRefPubMedPubMedCentral Yu J, Zhai X, Li X, Zhong C, Guo C, Yang F, Yuan Y, Zheng S (2017) Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci Rep 7:14265CrossRefPubMedPubMedCentral
24.
go back to reference Yamashita K, Watanabe M (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195–199CrossRefPubMed Yamashita K, Watanabe M (2009) Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci 100:195–199CrossRefPubMed
25.
go back to reference Li X, Kong L, Liao S, Lu J, Ma L, Long X (2017) The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi J Gastroenterol 23:28–33CrossRefPubMedPubMedCentral Li X, Kong L, Liao S, Lu J, Ma L, Long X (2017) The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi J Gastroenterol 23:28–33CrossRefPubMedPubMedCentral
26.
go back to reference Wu Y, Gong L, Xu J, Mou Y, Xu X, Qian Z (2017) The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer. Onco Targets Ther 10:5827–5834CrossRefPubMedPubMedCentral Wu Y, Gong L, Xu J, Mou Y, Xu X, Qian Z (2017) The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer. Onco Targets Ther 10:5827–5834CrossRefPubMedPubMedCentral
27.
go back to reference Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G (2017) Current and future biomarkers in colorectal cancer. Ann Gastroenterol 30:613–621PubMedPubMedCentral Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G (2017) Current and future biomarkers in colorectal cancer. Ann Gastroenterol 30:613–621PubMedPubMedCentral
28.
go back to reference Sugai T, Yoshida M, Eizuka M, Uesugii N, Habano W, Otsuka K, Sasaki A, Yamamoto E, Matsumoto T, Suzuki H (2017) Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clin Epigenetics 9:55CrossRefPubMedPubMedCentral Sugai T, Yoshida M, Eizuka M, Uesugii N, Habano W, Otsuka K, Sasaki A, Yamamoto E, Matsumoto T, Suzuki H (2017) Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa. Clin Epigenetics 9:55CrossRefPubMedPubMedCentral
29.
go back to reference Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JKV, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124–1132CrossRefPubMed Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JKV, Rao JS, Shuber A, Markowitz SD (2005) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124–1132CrossRefPubMed
30.
go back to reference Huang S, Zhong X, Gao J, Song R, Wu H, Zi S et al (2014) Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma. Biomed Res Int 2014:256723PubMedPubMedCentral Huang S, Zhong X, Gao J, Song R, Wu H, Zi S et al (2014) Coexpression of SFRP1 and WIF1 as a prognostic predictor of favorable outcomes in patients with colorectal carcinoma. Biomed Res Int 2014:256723PubMedPubMedCentral
31.
go back to reference Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, Dahl E (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488CrossRefPubMed Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, Huszka C, Knüchel R, Dahl E (2006) Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 25:3479–3488CrossRefPubMed
32.
go back to reference Ba S, Xuan Y, Long ZW, Chen HY, Zheng SS (2017) MicroRNA-27a promotes the proliferation and invasiveness of Colon Cancer cells by targeting SFRP1 through the Wnt/beta-catenin signaling pathway. Cell Physiol Biochem 42:1920–1933CrossRefPubMed Ba S, Xuan Y, Long ZW, Chen HY, Zheng SS (2017) MicroRNA-27a promotes the proliferation and invasiveness of Colon Cancer cells by targeting SFRP1 through the Wnt/beta-catenin signaling pathway. Cell Physiol Biochem 42:1920–1933CrossRefPubMed
33.
go back to reference Liu Y, Zhou Q, Zhou D, Huang C, Meng X, Li J (2017) Secreted frizzled-related protein 2-mediated cancer events: Friend or foe? Pharmacol Rep 69:403–8 Liu Y, Zhou Q, Zhou D, Huang C, Meng X, Li J (2017) Secreted frizzled-related protein 2-mediated cancer events: Friend or foe? Pharmacol Rep 69:403–8
34.
go back to reference Worm Orntoft MB (2018) Review of blood-based colorectal Cancer screening: how far are circulating cell-free DNA methylation markers from clinical implementation? Clin Colorectal Cancer 17:e415–ee33CrossRefPubMed Worm Orntoft MB (2018) Review of blood-based colorectal Cancer screening: how far are circulating cell-free DNA methylation markers from clinical implementation? Clin Colorectal Cancer 17:e415–ee33CrossRefPubMed
35.
go back to reference Harada T, Yamamoto E, Yamano HO, Nojima M, Maruyama R, Kumegawa K, Ashida M, Yoshikawa K, Kimura T, Harada E, Takagi R, Tanaka Y, Aoki H, Nishizono M, Nakaoka M, Tsuyada A, Niinuma T, Kai M, Shimoda K, Shinomura Y, Sugai T, Imai K, Suzuki H (2014) Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer. Cancer Prev Res 7:1002–1010CrossRef Harada T, Yamamoto E, Yamano HO, Nojima M, Maruyama R, Kumegawa K, Ashida M, Yoshikawa K, Kimura T, Harada E, Takagi R, Tanaka Y, Aoki H, Nishizono M, Nakaoka M, Tsuyada A, Niinuma T, Kai M, Shimoda K, Shinomura Y, Sugai T, Imai K, Suzuki H (2014) Analysis of DNA methylation in bowel lavage fluid for detection of colorectal cancer. Cancer Prev Res 7:1002–1010CrossRef
Metadata
Title
Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer
Authors
Haochang Hu
Tiangong Wang
Ranran Pan
Yong Yang
Bin Li
Cong Zhou
Jun Zhao
Yi Huang
Shiwei Duan
Publication date
01-04-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0505-6

Other articles of this Issue 2/2019

Pathology & Oncology Research 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine